Spring til hovednavigation Spring til søgning Spring til hovedindhold

Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses

  • Hospitalsenhed Midt
  • University of California
  • ​Nordsjællands Hospital

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

79 Downloads (Pure)

Fingeraftryk

Dyk ned i forskningsemnerne om 'Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses'. Sammen danner de et unikt fingeraftryk.
Sorter

Immunology and Microbiology